Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nurix
Biotech
Nurix drops BTK degrader, as Roche-partnered asset enters ph. 3
Nurix’s BTK degrader zelebrudomide may have survived a clinical hold, but that hasn’t stopped the California biotech from dropping the cancer drug.
James Waldron
Oct 13, 2026 3:16am
Roche bets $700M upfront on Nurix’s late-phase BTK degrader
Jun 8, 2026 4:41am
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
Sanofi pays $15M for another STAT6 degrader from Nurix collab
Jun 2, 2025 9:50am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
Sanofi pays Nurix $15M upfront for autoimmune degrader
Apr 2, 2025 8:10am
